Home » Stocks » RNLX

Renalytix AI PLC (RNLX)

Stock Price: $27.61 USD -1.38 (-4.76%)
Updated May 11, 2021 4:00 PM EDT - Market closed
After-hours: $27.90 +0.29 (1.05%) May 11, 5:23 PM
Market Cap 1.06B
Revenue (ttm) 400,000
Net Income (ttm) n/a
Shares Out 36.02M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 11
Last Price $27.61
Previous Close $28.99
Change ($) -1.38
Change (%) -4.76%
Day's Open 28.21
Day's Range 27.28 - 28.73
Day's Volume 65,608
52-Week Range 9.91 - 33.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

NEW YORK, May 4, 2021 /PRNewswire/ -- Kantaro Biosciences, LLC, a joint venture between the Mount Sinai Health System and RenalytixAI (LSE: RENX) (NASDAQ: RNLX), announced today that COVID-SeroKlir, its...

Other stocks mentioned: TECH
1 week ago - PRNewsWire

Renalytix AI plc (NASDAQ: RNLX) stock is rising on the heels of a 10-year contract from the United States Government to provide KidneyIntelX early-stage kidney disease bioprognostic testing services. Th...

2 weeks ago - Benzinga

Data from 1,325 CANVAS Participants with Baseline DKD Scored with KidneyIntelX Presented at International Society of Nephrology World Congress of Nephrology 2021 Data from 1,325 CANVAS Participants with...

3 weeks ago - GlobeNewsWire

Agreement provides RenalytixAI with exclusive option to access intellectual property surrounding a comprehensive panel of novel biomarkers in kidney disease Agreement provides RenalytixAI with exclusive...

3 weeks ago - GlobeNewsWire

Value of KidneyIntelX Testing Demonstrated by Data from 401 Physician Study Presented at National Kidney Foundation 2021 Spring Clinical Meetings Value of KidneyIntelX Testing Demonstrated by Data from ...

1 month ago - GlobeNewsWire

Clinical findings published in the April issue of Diabetologia, the official journal of the European Association for the Study of Diabetes Clinical findings published in the April issue of Diabetologia,...

1 month ago - GlobeNewsWire

NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of ki...

2 months ago - GlobeNewsWire

Innovative partnership to enable health system-wide approach to help delay or prevent progression in the earliest stages while advancing genetics research for detection, prognosis and treatment of chron...

2 months ago - GlobeNewsWire

NEW YORK, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) (“RenalytixAI” or the “Company”), the artificial intelligence-enabled in vitro diagnostics company, focused on opt...

2 months ago - GlobeNewsWire

Creates Pathway for Beneficiary Access to KidneyIntelX for Medicare Beneficiary Kidney Disease Populations Creates Pathway for Beneficiary Access to KidneyIntelX for Medicare Beneficiary Kidney Disease ...

3 months ago - GlobeNewsWire

Renalytix AI (RNLX) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

4 months ago - Zacks Investment Research

First-of-its-kind program combines early risk assessment of kidney decline and comprehensive care management to help slow kidney disease progression, improve care coordination and reduce costs First-of-...

4 months ago - GlobeNewsWire

NEW YORK, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kid...

4 months ago - GlobeNewsWire

NEW YORK, Dec. 2, 2020 /PRNewswire/ --The National Kidney Foundation (NKF) announced today a partnership with Renalytix AI (NASDAQ:RNLX) to improve kidney disease diagnosis and assessment in the earlies...

5 months ago - PRNewsWire

AIM ImmunoTech (NYSE: AIM) shares are trading higher on Wednesday after the company dosed its first patient in a study evaluating ampligen as part of combination treatment for patients with cancer and C...

Other stocks mentioned: AIM, ANPC
5 months ago - Benzinga

About RNLX

Renalytix AI plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record, and systems to generate a unique patient risk score. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed produc... [Read more...]

Industry
Diagnostics & Research
IPO Date
Jul 17, 2020
Stock Exchange
NASDAQ
Ticker Symbol
RNLX
Full Company Profile

Financial Performance

Financial Statements